| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |